Moderna CEO Stephane Bancel attends a meeting with President Donald Trump at the White House in March.Moderna, one of the frontrunners in developing a coronavirus vaccine, saw its stock fall by about 10% Tuesday morning, as investors weigh the market for a COVID-19 shot.
While Foroohar expects Moderna's vaccine to succeed in trials, he's not convinced about the commercial opportunity. As a frontrunner in the race for a COVID-19 shot, Moderna has seen its stock surge in 2020, from about $20 to a peak of $95 in July. Foroohar outlined three specific reasons that Moderna could fail to make big profits from its vaccine, even if the shot itself works to prevent the virus.Over the first few months of the pandemic, Moderna was well ahead of other companies in starting human testing and generating early data. But pharmaceutical giants like Pfizerto pivotal data showing whether or not their vaccine candidates work.
Deutschland Neuesten Nachrichten, Deutschland Schlagzeilen
Similar News:Sie können auch ähnliche Nachrichten wie diese lesen, die wir aus anderen Nachrichtenquellen gesammelt haben.
Herkunft: BusinessInsider - 🏆 729. / 51 Weiterlesen »